Oxidative Stress, Telomere Shortening, and Apoptosis Associated to Sarcopenia and Frailty in Patients with Multimorbidity.

dc.contributor.authorBernabeu-Wittel, Máximo
dc.contributor.authorGómez-Díaz, Raquel
dc.contributor.authorGonzález-Molina, Álvaro
dc.contributor.authorVidal-Serrano, Sofía
dc.contributor.authorDíez-Manglano, Jesús
dc.contributor.authorSalgado, Fernando
dc.contributor.authorSoto-Martín, María
dc.contributor.authorOllero-Baturone, Manuel
dc.contributor.authorOn Behalf Of The Proteo Researchers,
dc.date.accessioned2025-01-07T15:56:59Z
dc.date.available2025-01-07T15:56:59Z
dc.date.issued2020-08-18
dc.description.abstractThe presence of oxidative stress, telomere shortening, and apoptosis in polypathological patients (PP) with sarcopenia and frailty remains unknown. Multicentric prospective observational study in order to assess oxidative stress markers (catalase, glutathione reductase (GR), total antioxidant capacity to reactive oxygen species (TAC-ROS), and superoxide dismutase (SOD)), absolute telomere length (aTL), and apoptosis (DNA fragmentation) in peripheral blood samples of a hospital-based population of PP. Associations of these biomarkers to sarcopenia, frailty, functional status, and 12-month mortality were analyzed. Of the 444 recruited patients, 97 (21.8%), 278 (62.6%), and 80 (18%) were sarcopenic, frail, or both, respectively. Oxidative stress markers (lower TAC-ROS and higher SOD) were significantly enhanced and aTL significantly shortened in patients with sarcopenia, frailty or both syndromes. No evidence of apoptosis was detected in blood leukocytes of any of the patients. Both oxidative stress markers (GR, p = 0.04) and telomere shortening (p = 0.001) were associated to death risk and to less survival days. Oxidative stress markers and telomere length were enhanced and shortened, respectively, in blood samples of polypathological patients with sarcopenia and/or frailty. Both were associated to decreased survival. They could be useful in the clinical practice to assess vulnerable populations with multimorbidity and of potential interest as therapeutic targets.
dc.identifier.doi10.3390/jcm9082669
dc.identifier.issn2077-0383
dc.identifier.pmcPMC7464426
dc.identifier.pmid32824789
dc.identifier.pubmedURLhttps://pmc.ncbi.nlm.nih.gov/articles/PMC7464426/pdf
dc.identifier.unpaywallURLhttps://www.mdpi.com/2077-0383/9/8/2669/pdf?version=1597749765
dc.identifier.urihttps://hdl.handle.net/10668/27520
dc.issue.number8
dc.journal.titleJournal of clinical medicine
dc.journal.titleabbreviationJ Clin Med
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.organizationSAS - Hospital Universitario Juan Ramón Jiménez
dc.organizationSAS - Hospital Universitario Regional de Málaga
dc.organizationSAS - Hospital San Juan de Dios del Aljarafe
dc.organizationInstituto de Investigación Biomédica de Sevilla (IBIS)
dc.pubmedtypeJournal Article
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectapoptosis
dc.subjectfrailty
dc.subjectmultimorbidity
dc.subjectoxidative stress
dc.subjectpolypathological patients
dc.subjectsarcopenia
dc.subjecttelomere length
dc.titleOxidative Stress, Telomere Shortening, and Apoptosis Associated to Sarcopenia and Frailty in Patients with Multimorbidity.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number9

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PMC7464426.pdf
Size:
265.87 KB
Format:
Adobe Portable Document Format